Ureshino H, Kamachi K, Nishioka A, et al. - Given cessation of tyrosine kinase inhibitors (TKIs) now represents a feasible treatment goal for cases with chronic phase chronic myeloid leukemia (CML-CP), but it remains unclear if TKI can be discontinued safely again in such patients who re-achieve a durable deep molecular response (DMR), thus, researchers herein retrospectively evaluated first, second, and third attempts to discontinue TKIs in patients experiencing CML-CP. A sustained treatment-free remission (TFR) was achieved in 28 of 53 patients, at the first attempt. Subsequently, a second TKI stop was attempted in 10 of 25 patients, and in all cases, this was post-receipt of second-generation TKIs. Successful achievement of TFR was noted in four of 10 patients. TKIs were re-administered to all patients who relapsed at the second TKI cessation attempt, and these patients soon attained at least a major molecular remission. A loss of MR ^4.5 was observed, at 3 months post-TKI stop, in all six second relapse patients. These data indicate the feasibility of second and third attempts to successfully stop TKI treatment in CML-CP patients.